Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Embracer in connection with a new SEK 3,000,000,000 credit facility
Mandate

Vinge has advised Embracer in connection with a new SEK 3,000,000,000 credit facility

December 18, 2020 Banking and Finance

Vinge has advised Embracer Group AB (publ) in connection with the signing of a new SEK 3,000,000,000 credit facility for, amongst other things, M&A purposes, with Nordea Bank Abp, filial i Sverige.

Embracer Group is the parent company of businesses developing and publishing PC, console and mobile games for the global games market. With its head office based in Karlstad, Sweden, Embracer Group has a global presence through its six operative groups: THQ Nordic GmbH, Koch Media GmbH/Deep Silver, Coffee Stain AB, Amplifier Game Invest, Saber Interactive and DECA Games. The Group has 55 internal game development studios and is engaging more than 5,000 employees and contracted employers in more than 40 countries.

Vinge’s team consisted of Louise Brorsson Salomon, Lionardo Ojeda and Felix Möller.

 

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024